Quintiles News 2012:Quintiles opens BPO centre in China, invests in biomarker company

Quintiles has announced 2 initiatives that replicate compelling trends within the current drug development space: outsourcing to China and also the would like for viable biomarkers to underpin personalised cancer therapy.

The news from China is that the US-based biopharmaceutical services company has opened a business method outsourcing (BPO) and project management centre of excellence in Dalian, following the lead of Quintiles’ existing BPO centre in Bangalore, India.  

As a serious town in north-east China with a multilingual workforce, Dalian is ideally suited to serve the japanese, Chinese and South Korean biopharmaceutical markets, Quintiles noted.

The new workplace can give information management, biostatistics, medical writing, pharmacovigilance and post-marketing safety surveillance services, yet as back-office support for administrative functions. it'll additionally duplicate clinical operations for study sites in north-east China.

Valuable resources

Dalian’s strategic location and talent pool can enable Quintiles to supply clinical services in English, Japanese, Korean and Mandarin, including a cultural understanding of the city’s neighbouring countries, the corporate said.

These are valuable resources for each North Asian and world customers trying to expand within the region or to make sure business continuity through resource diversification, it added.

Quintiles’ Bangalore BPO center currently has quite one,000 individuals supporting world clinical studies.

The latest announcement comes laborious on the heels of Quintiles launching its own contract analysis organisation, Kun Tuo, in China.  

On that occasion, Ling Zhen, general manager, Quintiles China, highlighted the company’s “aggressive” growth arrange for China, including doubling overall workers numbers throughout 2012.

Quintiles expects staffing at the Dalian centre to grow to five hundred over successive many years as services become absolutely established. Dalian are the company’s fourth hub workplace in bigger China, joining existing operations in Beijing, Shanghai and Hong Kong. 

Biomarker venture

The biomarker venture is Oxford Cancer Biomarkers, a corporation spun out from the University of Oxford with investment from Quintiles, that is that the biggest shareholder.

Oxford Cancer Biomarkers can give oncology consulting services and develop new biomarkers using CancerNav, a proprietary DNA- and protein-based assay technology platform invented by Nick La Thangue, chair of cancer biology at Oxford University. 

La Thangue could be a major shareholder in Oxford Cancer Biomakers, alongside the University of Oxford and David Kerr, professor of cancer drugs at the University, who can function the new company’s chief medical officer.

“Biomarkers hold nice promise to boost trial success rates by identifying patient sub-groups possibly to reply to treatment, increasing the likelihood of trial success and improving patient safety,” commented Ben Cons, vp, Quintiles company Development. 

Quintiles’ investment in Oxford Cancer Biomarkers “is more proof of our commitment to supply biopharma and healthcare service suppliers with the tools, experience and services required to extend R&D productivity and speed, and higher the lives of patients”, Cons added.
Read more here

0 comments:

Post a Comment

Thank You for Your Valuable Comment.